Look out, Teva--Novartis' Copaxone generic is off to a speedy start

The launch for Glatopa, the new generic of Teva's ($TEVA) Copaxone from Novartis' ($NVS) Sandoz, is still in the very early going. But so far, things look good--very good--for the Swiss pharma giant. Through one week of launch, Glatopa racked up 18 prescriptions, and that number soared to 472 by the two-week mark, according to IMS Health data. And as Evercore ISI analyst Umer Raffat wrote in a Friday note to clients, that initial ramp looks a lot like that of Biogen's ($BIIB) high-flying Tecfidera and Teva's own long-lasting Copaxone, which has blown away analyst expectations. More from FiercePharmaMarketing